12:00 AM
 | 
Dec 16, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Status

PSMA ADC: Completed Phase II enrollment

Progenics completed enrollment of 83 patients who had progressive disease despite treatment with >=1 taxane-containing chemotherapy in an open-label, U.S. Phase II trial evaluating 2.5 mg/kg IV PSMA ADC given every 3 weeks for up to 8 doses. The company also...

Read the full 182 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >